On September 23, 2009
Playing Devil’s Advocate on the Talecris IPO: A Banker Provides the Contrarian View
Earlier this week, I argued that you’d have to be a fool to buy into the Talecris Biotherapeutics initial public offering. Now a banker presents the other side of the story.
0 Comments